Pancreatic Cancer
20 videos · last 6 months shuffled daily, then older videos newest first
▶
2:11 Local 10 on Daraxonrasib Results in Metastatic Pancreatic Cancer
WPLG Local 10 looks at a clinical trial in metastatic pancreatic cancer where patients taking the experimental drug daraxonrasib survived a median of 13 months from the start of treatment, against 6.5 months on standard treatment.
▶
1:48 GLEAM: Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel in CLDN18.2-positive mPAC
Wungki Park, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the background and findings from the Phase II GLEAM study (NCT03816163) of zolbetuximab plus gemcitabine and nab-paclitaxel in patients with CLDN18.2-positive metastatic pancreatic adenocarcinoma (mPAC).
▶
1:41 Emerging Cellular Therapies in Gastrointestinal Cancers
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, discusses emerging cellular therapies in gastrointestinal (GI) cancer, including an engineered T-cell receptor therapy against p53 which has shown promise in pancreatic cancer and a CAR T-cell therapy targeting CLDN18.2.
▶
20:20 New Breakthroughs in Pancreatic Cancer Treatment and Research
Shubham Pant, M.D., and David Hong, M.D., of MD Anderson on KRAS-targeted drugs in pancreatic cancer, including daraxonrasib, and the clinical trials and combinations being studied.
▶
1:21 Breakthrough Pancreatic Cancer Drug Trial
Michigan Medicine on daraxonrasib, an experimental pancreatic cancer drug that improved survival rates in a Phase 3 trial.
▶
2:41 Speak Up for Cancer Research: Gary Wight
Gary Wight, diagnosed with stage IV pancreatic cancer in 2024, enrolled in a clinical trial of a new medication and shares his experience.
▶
1:20 Daraxonrasib Approval in Metastatic Pancreatic Cancer
Ignacio Garrido-Laguna, MD, PhD, of Moffitt Cancer Center explains the FDA approval of daraxonrasib, a once-daily RAS-targeting pill, after a Phase 3 trial in which median overall survival was 13.2 months versus 6.7 months with chemotherapy.
▶
1:30 Daraxonrasib’s Approval Is for All Comers with Pancreatic Cancer
Nicholas Hornstein, MD, PhD, of the Zucker School of Medicine at Hofstra/Northwell explains that the August 2026 FDA approval of daraxonrasib in metastatic pancreatic adenocarcinoma makes it an option for patients not up for chemotherapy, for CancerNetwork.
▶
2:17 POLAR: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer
Wungki Park, MD, MS, Memorial Sloan Kettering Cancer Center explores background and findings from the Phase II POLAR trial (NCT04666740) of pembrolizumab and olaparib in homologous-recombination-deficient (HRD) metastatic pancreatic cancer.
▶
47:03 Clinically Meaningful Differences in Progressive Disease Trials
Berry Consultants' Dr. Scott Berry argues on the In the Interim podcast that responder analyses and time saved suit progressive-disease trials better than mean differences, citing pancreatic cancer, emphysema, Alzheimer's and IVF.
▶
39:29 ASCO 2026: Highlights and Analysis
Associate Professor Bishal Gyawali talks to ecancer about ASCO 2026 presentations across GI, pancreatic, lung, breast and prostate cancer, including daraxonrasib in metastatic pancreatic adenocarcinoma.
▶
53:13 KRAS and Pancreatic Cancer: Entering a New Era of Treatment
PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, hosts a panel discussion focused on KRAS and pancreatic cancer.
▶
3:31 BREAKTHROUGH: New Pancreatic Cancer Vaccine Shows Stunning Promise
Fox News on early results from an experimental pancreatic cancer vaccine, which produced a lasting immune response in most high-risk patients in the trial.
▶
1:41 RASolute 302: Daraxonrasib vs Chemotherapy in Pancreatic Cancer
WeTrials summarises the randomized Phase 3 RASolute 302 trial, in which 500 people with previously treated metastatic pancreatic cancer received daraxonrasib or chemotherapy, with median overall survival of 13.2 versus 6.7 months.
▶
1:23 Is CLDN18.2 a Promising Target in Pancreatic Cancer?
Wungki Park, MD, MS, Memorial Sloan Kettering Cancer Center, explores the development of CLDN18.2-targeting therapies in pancreatic cancer, highlighting that bispecific antibodies, CAR T-cell therapies and antibody-drug conjugates are all under investigation.
▶
58:46 [LTRN Webinar] Inside the Data - LP-184 Phase 1a Results and Future Trials with Dr. Igor Astsaturov
Lantern Pharma and Dr. Igor Astsaturov of Fox Chase Cancer Center review Phase 1a results for LP-184, a synthetic lethal candidate for advanced solid tumours, and plans for further trials.
▶
4:41 The Innovation Behind RenovoRx's Therapy Platform
RenovoRx describes its trans-arterial micro-perfusion platform for delivering approved chemotherapy locally, and its lead candidate RenovoGem, being studied in the Phase 3 TIGeR-PaC trial in pancreatic cancer.
▶
2:11 Clinical Trial Looks at Type 2 Diabetes as an Indicator for Pancreatic Cancer
A clinical trial sponsored by Bluestar Genomics is underway in Palm Beach, Florida and is looking for patients recently diagnosed with Type 2 Diabetes to see if Type 2 Diabetes can be used as an indicator and way of detecting pancreatic cancer in its early stages.
▶
2:47 RenovoTAMP™: Trans-Arterial Micro-Perfusion Therapy Platform
RenovoRx on RenovoTAMP, a platform for delivering chemotherapy directly to hard-to-treat tumours, now in a Phase 3 trial in locally advanced pancreatic cancer.
▶
1:28:52 KRAS Inhibitors and Clinical Trials in Pancreatic Cancer
Andrew Aguirre, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses KRAS inhibitors, biomarker testing, current clinical trials and the path to drug approval in pancreatic cancer, in a KRAS Kickers webinar for patients and caregivers.